Hydroxycarbamide (also known as hydroxyurea) is an antineoplastic antimetabolite used in treatment protocols for chronic myeloproliferative disorders, and in the management of sickle cell disease.
EML status history
First added in 2009 (TRS 958) for Chronic myeloid leukaemia, not elsewhere classified
Added in 2011 (TRS 965) for Other specified sickle cell disorders or other haemoglobinopathies
- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
Other medicines for haemoglobinopathies
- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg